- Home
- BMRA vs BLRX Comparison
BMRA vs BLRX Comparison
Compare BMRA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- BLRX
- Stock Information
- Founded
- BMRA 1971
- BLRX 2003
- Country
- BMRA United States
- BLRX Israel
- Employees
- BMRA N/A
- BLRX N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- BLRX Health Care
- Exchange
- BMRA Nasdaq
- BLRX Nasdaq
- Market Cap
- BMRA 11.2M
- BLRX 12.2M
- IPO Year
- BMRA N/A
- BLRX 2011
- Fundamental
- Price
- BMRA $0.57
- BLRX $3.10
- Analyst Decision
- BMRA
- BLRX Buy
- Analyst Count
- BMRA 0
- BLRX 2
- Target Price
- BMRA N/A
- BLRX $26.00
- AVG Volume (30 Days)
- BMRA 187.3K
- BLRX 26.4K
- Earning Date
- BMRA 04-11-2025
- BLRX 05-27-2025
- Dividend Yield
- BMRA N/A
- BLRX N/A
- EPS Growth
- BMRA N/A
- BLRX N/A
- EPS
- BMRA N/A
- BLRX N/A
- Revenue
- BMRA $5,578,000.00
- BLRX $28,940,000.00
- Revenue This Year
- BMRA N/A
- BLRX N/A
- Revenue Next Year
- BMRA N/A
- BLRX N/A
- P/E Ratio
- BMRA N/A
- BLRX N/A
- Revenue Growth
- BMRA 1.40
- BLRX 502.92
- 52 Week Low
- BMRA $0.24
- BLRX $2.85
- 52 Week High
- BMRA $1.27
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- BMRA 40.83
- BLRX 41.70
- Support Level
- BMRA $0.55
- BLRX $3.01
- Resistance Level
- BMRA $0.74
- BLRX $3.61
- Average True Range (ATR)
- BMRA 0.05
- BLRX 0.22
- MACD
- BMRA -0.01
- BLRX 0.02
- Stochastic Oscillator
- BMRA 9.84
- BLRX 32.89
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.